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Haem is required for many cellular processes including haemoglobin synthesis in erythroid
cells, where the majority of the haem in the body is produced and utilised. Its synthesis
requires tight regulation to prevent toxic levels of free haem from arising. 5-Aminolevulinate
s¡mthase 2 (ALAS2) is the first and rate limitingenzpe in the biosynthesis of haem in
erythroid cells. Thus, the regulation of ALAS2 expression is critical for maintaining and
controlling haem production during the process of erythroid cell differentiation. A major aim
of this study was to identiff the regulatory elements within the ALAS2 gene that are involved
in controlling transcription of ALAS2 during erythropoietin (Epo) stimulated erythroid
differentiation. In order to investigate the regulation of ALAS2 transcription in the context of
red blood cell maturation, an erythroid cell line, J2E,that terminally differentiates in response
to Epo treatment was employed in this study.
Human ALAS2 promoter deletion studies demonstrated that the first 293bp of the proximal
promoter was sufficient to enhance transcription in response to Epo induced differentiation of
the J2E cells. Introns 1 and 8 exhibited Epo responsive enhancer activity with intron 8
proving to be the stronger transcriptional activator in response to Epo. Transcription factor
binding sites located in the 3' end of intron 8 that are critical to intron 8 Epo responsive
enhancer activity were also identified. Preliminary studies on the effect of the coactivators
CREB binding protein (CBP) and p300 on ALAS2 expression in response to Epo stimulation
were conducted and suggested a potential involvement of these factors in regulating ALAS2
transcription.
Defective haem synthesis, as a result of point mutations in the human ALAS2 gene, has been
implicated in a blood disorder called X-linked sideroblastic anaemia (XLSA). XLSA is
characterised by the presence of iron loaded mitochondria surrounding the nucleus in
erythroblasts of the bone marrow. Anaemia, associated with a cycle of ineffective
erythropoiesis that is linked to increased intestinal iron absorption and the secondary effect of
iron overload is exhibited by XLSA patients. Point mutations in the ALAS2 gene of XLSA
probands have been identified and two associated mutations, C1215G in exon 8 and Cl283T
in exon 9 were selected as a basis for a murine model for XLSA. Thus, the aim of this project
was to develop an animal model for XLSA to investigate the role of ALAS2 in this blood
disorder and the associated defects in iron metabolism. A gene targeting approach using
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embryonic stem (ES) cells was employed and several strategies trialed. A potential ALAS2
targeted ES cell line containing the Cl159G point mutation in exon 8 (equivalent to the
human mutation) was generated, with further characterisation required.
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